Since our founding in 1976, Sofinnova has been active in life science investing and has primarily focused on therapeutic drugs over the last decade. We are a clinical-stage biopharmaceutical investment firm with approximately $3.0B in assets under management and committed capital.* We invest in both private and public equity of therapeutics-focused companies. Our Mission: to improve the lives of patients through science. We strive to provide outstanding results for those we serve: patients, entrepreneurs, and the investors that entrust us with their capital.